Melanoma Research Pioneer Jeffrey S Weber, MD, PhD, Dies. (Cancer Network)
Cancer Network (8/19) Jeffrey S. Weber, MD, PhD, the Laura and Isaac Perlmutter Professor of Oncology, Department of Medicine, Division of Hematology and Medical Oncology, Perlmutter Cancer Center, a 2016 Giants of Cancer Care award winner in Melanoma and the Laura and Isaac Perlmutter Professor of Oncology in the Department of Medicine at NYU Grossman School of Medicine, has died, according to an announcement from The Melanoma Research Alliance; Dr. Weber also served as deputy director of the Laura and Isaac Perlmutter Cancer Center, director of the Experimental Therapeutics Program, and co-leader of the Clinical Melanoma Program Board at NYU Langone Health.
Also reporting is OncLive (8/19).
As Denials Pile Up, NFL Settlement Ignores ‘Critical’ Tests. (Washington Post)
The Washington Post (8/19) In 2016 and 2017, the FDA approved two software tools that significantly enhanced the precision of brain MRIs, helping doctors identify whether areas of patients’ brains were alarmingly small when compared with those of healthy people the same age; Thomas M. Wisniewski, MD, the Gerald J. and Dorothy R. Friedman Professor of New York University Alzheimer’s Disease Center, Department of Neurology, professor, Departments of Pathology, and Psychiatry, associate chair, Research Department of Neurology, said, “It really makes a difference if I know that someone’s hippocampal volume is at the 10th percentile for their age...I view it as absolutely critical in helping me come up with a diagnosis.”
Study: Best Options To Treat Obesity. (Your Health Magazine)
Your Health Magazine (8/19) A study from the Department of Medicine at NYU Grossman School of Medicine reveals that bariatric surgery is the most effective weight loss solution for patients, significantly reducing risks associated with obesity, including type 2 diabetes, hypertension, cardiovascular disease, osteoarthritis, premature death, and sleep disorders, in a country where 42% of people suffer from obesity.
New AI Tool Offers Detailed Cancer Prognosis And Recurrence Predictions. (Targeted Oncology)
Targeted Oncology (8/19) Researchers at NYU Langone Health’s Perlmutter Cancer Center and the University of Glasgow developed a self-taught artificial intelligence (AI) tool for diagnosing adenocarcinoma, which, according to Aristotelis Tsirigos, PhD, professor, Department of Medicine, Division of Precision Medicine, and Department of Pathology, Perlmutter Cancer Center, and co-director of precision medicine and director of its Applied Bioinformatics Laboratories, “accurately distinguished between lung adenocarcinoma and squamous cell cancers 99% of the time and predicted cancer recurrence with 72% accuracy,” outperforming pathologists’ 64% accuracy.
ADR Meta-Analysis Supports CRC Screening At Age 45. (Gastroenterology Learning Network)
Gastroenterology Learning Network (8/19) The pooled detection rate for adenomas in patients aged 45 to 49 years with average colorectal cancer risk was 28.2%, according to a systematic review and meta-analysis published in The American Journal of Gastroenterology, with corresponding author Aasma Shaukat, MD, MPH, the Robert M. and Mary H. Glickman Professor of Medicine, Department of Medicine, Division of Gastroenterology and Hepatology, professor, Department of Population Health, and study coauthors writing, “A recent guidance published by the American College of Physicians recently suggested to start screening at 50 years of age in average-risk asymptomatic patients.”
Three Neurocognitive Profiles Identified For Children Born Prematurely. (Drug Information Online)
Drug Information Online (8/19) A study published in Child Development categorizes prematurely born children into three distinct neurocognitive profiles, with Iris Menu, PhD, postdoctoral fellow, and colleagues using latent profile analysis on data from the Adolescent Brain and Cognitive Development study to identify developmental trajectories; Dr. Menu stated, “Based on these results, we call for the launch of social and structural interventions that ensure all preterm-born children receive equitable care.”
Also reporting are Physician’s Weekly (8/20) and HealthDay (8/19).
First At-Home Syphilis Antibody Test Gets FDA Authorization As STD Cases Spike In US. (Fox News)
Fox News (8/19) The US Food and Drug Administration has granted marketing authorization for the first at-home syphilis test, which Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation, described as “especially important,” emphasizing that “the earlier syphilis exposure/diagnosis is made the better.”
In a separate article, Fox News (8/19) A respiratory disease known as parvovirus B19 “is highly contagious and can spread asymptomatically,” said Marc K. Siegel, MD, clinical professor, Department of Medicine, Division of General Internal Medicine and Clinical Innovation.
